September 26th 2024
The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Metrics to Determine Disease Clearance in Plaque Psoriasis
Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, discuss metrics to determine clearance in plaque psoriasis and how the provider’s expectations may be different from the patient’s expectations.
Importance of Quick Response to Treatment for Patients With Plaque Psoriasis
Lakshi Aldredge, MSN, ANP-BC, discusses how speed of treatment response guides treatment selection for the patient, taking patient preference into consideration. Jennifer Conner, MPAS, PA-C, comments on treatment failure in plaque psoriasis.
Approaches to Treatment of Plaque Psoriasis
Jennifer Conner, MPAS, PA-C, Terry Faleye, MPAS, PA-C, and Laura Bush, DMSc, PA-C, comment on approaches to treatment selection in managing plaque psoriasis, highlighting topical treatment in combination with other therapies.
Efficacy of Deucravacitinib in Plaque Psoriasis
Lakshi Aldredge, MSN, ANP-BC, reviews the mechanism of action of deucravacitinib, commenting on its efficacy in the treatment of plaque psoriasis.
The Role of Nurse Practitioners and Physician Assistants in Managing Plaque Psoriasis
Alexa Hetzel, MS, PA-C, leads a discussion on the role both physician assistants and nurse practitioners play in diagnosis and management of plaque psoriasis, commenting on the dermatology environment vs the primary care environment.